Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Biogen Inc., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Biogen Inc. debt to equity ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Biogen Inc. debt to equity ratio (including operating lease liability) improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Biogen Inc. debt to capital ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Biogen Inc. debt to capital ratio (including operating lease liability) improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Biogen Inc. debt to assets ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Biogen Inc. debt to assets ratio (including operating lease liability) improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Biogen Inc. financial leverage ratio increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022. |
Debt to Equity
Biogen Inc., debt to equity calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of notes payable | —) | 999,800) | 999,500) | 999,100) | 998,800) | —) | —) | —) | —) | —) | 1,501,800) | 1,495,800) | 1,495,300) | —) | —) | —) | —) | —) | 3,300) | 3,200) | 573,200) | 559,900) | 561,500) | |||||||
| Notes payable, excluding current portion | 6,279,200) | 6,277,400) | 6,275,700) | 6,274,000) | 6,272,300) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 4,459,900) | 4,459,000) | 4,458,200) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,929,400) | 5,935,000) | 5,938,300) | 5,954,000) | 5,952,700) | |||||||
| Total debt | 6,279,200) | 7,277,200) | 7,275,200) | 7,273,100) | 7,271,100) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 5,961,700) | 5,954,800) | 5,953,500) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Total Biogen Inc. shareholders’ equity | 12,775,500) | 11,872,500) | 11,242,300) | 10,896,200) | 10,429,900) | 10,751,900) | 10,682,200) | 10,700,300) | 10,758,500) | 11,308,700) | 12,546,900) | 13,343,200) | 13,995,900) | 12,952,900) | 13,829,900) | 13,039,600) | 13,766,600) | 12,260,900) | 14,053,700) | 12,612,800) | 12,860,500) | 11,585,200) | 11,479,000) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity1 | 0.49 | 0.61 | 0.65 | 0.67 | 0.70 | 0.68 | 0.68 | 0.69 | 0.69 | 0.66 | 0.48 | 0.45 | 0.43 | 0.46 | 0.43 | 0.46 | 0.43 | 0.48 | 0.42 | 0.47 | 0.51 | 0.56 | 0.57 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 4.35 | 4.98 | 4.51 | 4.98 | 5.96 | 6.53 | 6.24 | 6.58 | 5.70 | 5.94 | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 10.60 | 15.10 | 40.23 | 4.97 | 4.57 | 3.98 | 3.50 | 3.51 | 3.13 | 3.21 | 3.36 | 3.09 | 2.73 | 2.84 | 3.05 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 1.20 | 1.29 | 1.42 | 1.24 | 1.20 | 1.23 | 1.23 | 1.34 | 0.90 | 0.95 | 0.94 | 0.91 | 1.41 | 1.56 | 0.40 | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.41 | 0.43 | 0.47 | 0.49 | 0.54 | 0.48 | 0.50 | 0.53 | 0.57 | 0.62 | 0.84 | 0.72 | 0.54 | 0.32 | 0.30 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.58 | 1.97 | 1.77 | 1.88 | 2.20 | 2.56 | 2.35 | 2.94 | 3.51 | 3.99 | 5.60 | 5.88 | 4.50 | 5.68 | 6.44 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 1.20 | 1.30 | 1.32 | 1.27 | 1.29 | 1.53 | 1.59 | 1.73 | 1.68 | 1.34 | 1.09 | 1.09 | 1.19 | 1.15 | 1.21 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.43 | 0.43 | 0.44 | 0.46 | 0.48 | 0.48 | 0.51 | 0.56 | 0.59 | 0.48 | 0.45 | 0.47 | 0.50 | 0.48 | 0.50 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.68 | 0.73 | 0.78 | 0.87 | 0.74 | 0.80 | 1.16 | 1.26 | 0.98 | 1.12 | 1.07 | 1.02 | 0.97 | 0.96 | 0.94 | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.40 | 0.46 | 0.44 | 0.50 | 0.53 | 0.56 | 0.58 | 0.63 | 0.97 | 0.99 | 0.80 | 0.83 | 0.81 | 0.78 | 0.77 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.13 | 0.13 | 0.14 | 0.14 | 0.16 | 0.18 | 0.23 | 0.24 | 0.27 | 0.24 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.67 | 0.72 | 0.81 | 0.85 | 0.56 | 0.51 | 0.53 | 0.63 | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Debt to equity = Total debt ÷ Total Biogen Inc. shareholders’ equity
= 6,279,200 ÷ 12,775,500 = 0.49
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Biogen Inc. debt to equity ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Debt to Equity (including Operating Lease Liability)
Biogen Inc., debt to equity (including operating lease liability) calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of notes payable | —) | 999,800) | 999,500) | 999,100) | 998,800) | —) | —) | —) | —) | —) | 1,501,800) | 1,495,800) | 1,495,300) | —) | —) | —) | —) | —) | 3,300) | 3,200) | 573,200) | 559,900) | 561,500) | |||||||
| Notes payable, excluding current portion | 6,279,200) | 6,277,400) | 6,275,700) | 6,274,000) | 6,272,300) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 4,459,900) | 4,459,000) | 4,458,200) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,929,400) | 5,935,000) | 5,938,300) | 5,954,000) | 5,952,700) | |||||||
| Total debt | 6,279,200) | 7,277,200) | 7,275,200) | 7,273,100) | 7,271,100) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 5,961,700) | 5,954,800) | 5,953,500) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Long-term operating lease liabilities | 354,800) | 274,200) | 312,300) | 330,400) | 348,200) | 363,900) | 380,000) | 402,000) | 409,100) | 414,800) | 403,700) | 412,700) | 410,500) | 423,000) | 436,100) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 6,634,000) | 7,551,400) | 7,587,500) | 7,603,500) | 7,619,300) | 7,633,100) | 7,647,200) | 7,828,200) | 7,834,100) | 7,838,600) | 6,365,400) | 6,367,500) | 6,364,000) | 6,371,500) | 6,379,300) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Total Biogen Inc. shareholders’ equity | 12,775,500) | 11,872,500) | 11,242,300) | 10,896,200) | 10,429,900) | 10,751,900) | 10,682,200) | 10,700,300) | 10,758,500) | 11,308,700) | 12,546,900) | 13,343,200) | 13,995,900) | 12,952,900) | 13,829,900) | 13,039,600) | 13,766,600) | 12,260,900) | 14,053,700) | 12,612,800) | 12,860,500) | 11,585,200) | 11,479,000) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to equity (including operating lease liability)1 | 0.52 | 0.64 | 0.67 | 0.70 | 0.73 | 0.71 | 0.72 | 0.73 | 0.73 | 0.69 | 0.51 | 0.48 | 0.45 | 0.49 | 0.46 | 0.46 | 0.43 | 0.48 | 0.42 | 0.47 | 0.51 | 0.56 | 0.57 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.06 | 0.04 | 0.04 | 0.05 | 0.03 | 0.06 | 0.06 | 0.08 | 0.08 | 0.06 | 0.09 | 0.11 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Total Biogen Inc. shareholders’ equity
= 6,634,000 ÷ 12,775,500 = 0.52
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Biogen Inc. debt to equity ratio (including operating lease liability) improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Debt to Capital
Biogen Inc., debt to capital calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of notes payable | —) | 999,800) | 999,500) | 999,100) | 998,800) | —) | —) | —) | —) | —) | 1,501,800) | 1,495,800) | 1,495,300) | —) | —) | —) | —) | —) | 3,300) | 3,200) | 573,200) | 559,900) | 561,500) | |||||||
| Notes payable, excluding current portion | 6,279,200) | 6,277,400) | 6,275,700) | 6,274,000) | 6,272,300) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 4,459,900) | 4,459,000) | 4,458,200) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,929,400) | 5,935,000) | 5,938,300) | 5,954,000) | 5,952,700) | |||||||
| Total debt | 6,279,200) | 7,277,200) | 7,275,200) | 7,273,100) | 7,271,100) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 5,961,700) | 5,954,800) | 5,953,500) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Total Biogen Inc. shareholders’ equity | 12,775,500) | 11,872,500) | 11,242,300) | 10,896,200) | 10,429,900) | 10,751,900) | 10,682,200) | 10,700,300) | 10,758,500) | 11,308,700) | 12,546,900) | 13,343,200) | 13,995,900) | 12,952,900) | 13,829,900) | 13,039,600) | 13,766,600) | 12,260,900) | 14,053,700) | 12,612,800) | 12,860,500) | 11,585,200) | 11,479,000) | |||||||
| Total capital | 19,054,700) | 19,149,700) | 18,517,500) | 18,169,300) | 17,701,000) | 18,021,100) | 17,949,400) | 18,126,500) | 18,183,500) | 18,732,500) | 18,508,600) | 19,298,000) | 19,949,400) | 18,901,400) | 19,773,100) | 18,976,100) | 19,697,700) | 18,189,300) | 19,986,400) | 18,551,000) | 19,372,000) | 18,099,100) | 17,993,200) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital1 | 0.33 | 0.38 | 0.39 | 0.40 | 0.41 | 0.40 | 0.40 | 0.41 | 0.41 | 0.40 | 0.32 | 0.31 | 0.30 | 0.31 | 0.30 | 0.31 | 0.30 | 0.33 | 0.30 | 0.32 | 0.34 | 0.36 | 0.36 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.81 | 0.83 | 0.82 | 0.83 | 0.86 | 0.87 | 0.86 | 0.87 | 0.85 | 0.86 | 1.12 | 1.14 | 1.27 | 1.30 | 1.27 | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.91 | 0.94 | 0.98 | 0.83 | 0.82 | 0.80 | 0.78 | 0.78 | 0.76 | 0.76 | 0.77 | 0.76 | 0.73 | 0.74 | 0.75 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.54 | 0.56 | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.47 | 0.49 | 0.48 | 0.48 | 0.59 | 0.61 | 0.28 | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.29 | 0.30 | 0.32 | 0.33 | 0.35 | 0.32 | 0.33 | 0.35 | 0.37 | 0.38 | 0.46 | 0.42 | 0.35 | 0.24 | 0.23 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.61 | 0.66 | 0.64 | 0.65 | 0.69 | 0.72 | 0.70 | 0.75 | 0.78 | 0.80 | 0.85 | 0.85 | 0.82 | 0.85 | 0.87 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.54 | 0.56 | 0.57 | 0.56 | 0.56 | 0.60 | 0.61 | 0.63 | 0.63 | 0.57 | 0.52 | 0.52 | 0.54 | 0.54 | 0.55 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.30 | 0.30 | 0.31 | 0.31 | 0.33 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 | 0.31 | 0.32 | 0.33 | 0.33 | 0.33 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.41 | 0.42 | 0.44 | 0.46 | 0.42 | 0.44 | 0.54 | 0.56 | 0.50 | 0.53 | 0.52 | 0.50 | 0.49 | 0.49 | 0.48 | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.28 | 0.32 | 0.31 | 0.33 | 0.35 | 0.36 | 0.37 | 0.39 | 0.49 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.43 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.11 | 0.12 | 0.12 | 0.13 | 0.14 | 0.15 | 0.18 | 0.20 | 0.21 | 0.20 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.40 | 0.42 | 0.45 | 0.46 | 0.36 | 0.34 | 0.35 | 0.39 | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Debt to capital = Total debt ÷ Total capital
= 6,279,200 ÷ 19,054,700 = 0.33
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Biogen Inc. debt to capital ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Debt to Capital (including Operating Lease Liability)
Biogen Inc., debt to capital (including operating lease liability) calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of notes payable | —) | 999,800) | 999,500) | 999,100) | 998,800) | —) | —) | —) | —) | —) | 1,501,800) | 1,495,800) | 1,495,300) | —) | —) | —) | —) | —) | 3,300) | 3,200) | 573,200) | 559,900) | 561,500) | |||||||
| Notes payable, excluding current portion | 6,279,200) | 6,277,400) | 6,275,700) | 6,274,000) | 6,272,300) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 4,459,900) | 4,459,000) | 4,458,200) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,929,400) | 5,935,000) | 5,938,300) | 5,954,000) | 5,952,700) | |||||||
| Total debt | 6,279,200) | 7,277,200) | 7,275,200) | 7,273,100) | 7,271,100) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 5,961,700) | 5,954,800) | 5,953,500) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Long-term operating lease liabilities | 354,800) | 274,200) | 312,300) | 330,400) | 348,200) | 363,900) | 380,000) | 402,000) | 409,100) | 414,800) | 403,700) | 412,700) | 410,500) | 423,000) | 436,100) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 6,634,000) | 7,551,400) | 7,587,500) | 7,603,500) | 7,619,300) | 7,633,100) | 7,647,200) | 7,828,200) | 7,834,100) | 7,838,600) | 6,365,400) | 6,367,500) | 6,364,000) | 6,371,500) | 6,379,300) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Total Biogen Inc. shareholders’ equity | 12,775,500) | 11,872,500) | 11,242,300) | 10,896,200) | 10,429,900) | 10,751,900) | 10,682,200) | 10,700,300) | 10,758,500) | 11,308,700) | 12,546,900) | 13,343,200) | 13,995,900) | 12,952,900) | 13,829,900) | 13,039,600) | 13,766,600) | 12,260,900) | 14,053,700) | 12,612,800) | 12,860,500) | 11,585,200) | 11,479,000) | |||||||
| Total capital (including operating lease liability) | 19,409,500) | 19,423,900) | 18,829,800) | 18,499,700) | 18,049,200) | 18,385,000) | 18,329,400) | 18,528,500) | 18,592,600) | 19,147,300) | 18,912,300) | 19,710,700) | 20,359,900) | 19,324,400) | 20,209,200) | 18,976,100) | 19,697,700) | 18,189,300) | 19,986,400) | 18,551,000) | 19,372,000) | 18,099,100) | 17,993,200) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to capital (including operating lease liability)1 | 0.34 | 0.39 | 0.40 | 0.41 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.41 | 0.34 | 0.32 | 0.31 | 0.33 | 0.32 | 0.31 | 0.30 | 0.33 | 0.30 | 0.32 | 0.34 | 0.36 | 0.36 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.05 | 0.04 | 0.04 | 0.05 | 0.03 | 0.06 | 0.06 | 0.07 | 0.07 | 0.05 | 0.08 | 0.10 | 0.04 | 0.03 | 0.03 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 6,634,000 ÷ 19,409,500 = 0.34
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Biogen Inc. debt to capital ratio (including operating lease liability) improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Debt to Assets
Biogen Inc., debt to assets calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of notes payable | —) | 999,800) | 999,500) | 999,100) | 998,800) | —) | —) | —) | —) | —) | 1,501,800) | 1,495,800) | 1,495,300) | —) | —) | —) | —) | —) | 3,300) | 3,200) | 573,200) | 559,900) | 561,500) | |||||||
| Notes payable, excluding current portion | 6,279,200) | 6,277,400) | 6,275,700) | 6,274,000) | 6,272,300) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 4,459,900) | 4,459,000) | 4,458,200) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,929,400) | 5,935,000) | 5,938,300) | 5,954,000) | 5,952,700) | |||||||
| Total debt | 6,279,200) | 7,277,200) | 7,275,200) | 7,273,100) | 7,271,100) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 5,961,700) | 5,954,800) | 5,953,500) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Total assets | 24,854,200) | 25,081,400) | 23,614,400) | 23,877,300) | 23,806,700) | 24,470,400) | 23,854,700) | 24,618,900) | 24,934,100) | 25,511,800) | 26,119,200) | 27,234,300) | 27,484,000) | 26,287,600) | 26,445,500) | 25,288,900) | 25,492,200) | 23,952,900) | 26,090,100) | 23,652,600) | 23,073,200) | 21,759,000) | 21,195,900) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets1 | 0.25 | 0.29 | 0.31 | 0.30 | 0.31 | 0.30 | 0.30 | 0.30 | 0.30 | 0.29 | 0.23 | 0.22 | 0.22 | 0.23 | 0.22 | 0.23 | 0.23 | 0.25 | 0.23 | 0.25 | 0.28 | 0.30 | 0.31 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.49 | 0.51 | 0.51 | 0.52 | 0.54 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.74 | 0.75 | 0.65 | 0.65 | 0.65 | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 0.61 | 0.62 | 0.62 | 0.54 | 0.58 | 0.55 | 0.52 | 0.52 | 0.53 | 0.53 | 0.52 | 0.50 | 0.50 | 0.52 | 0.52 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 0.40 | 0.42 | 0.44 | 0.41 | 0.40 | 0.41 | 0.41 | 0.43 | 0.36 | 0.36 | 0.36 | 0.36 | 0.43 | 0.45 | 0.17 | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 0.24 | 0.25 | 0.26 | 0.27 | 0.29 | 0.26 | 0.27 | 0.28 | 0.30 | 0.31 | 0.38 | 0.35 | 0.29 | 0.19 | 0.18 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.33 | 0.36 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.36 | 0.39 | 0.39 | 0.42 | 0.39 | 0.40 | 0.41 | 0.42 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 0.40 | 0.42 | 0.42 | 0.39 | 0.41 | 0.44 | 0.45 | 0.46 | 0.48 | 0.43 | 0.40 | 0.40 | 0.42 | 0.41 | 0.42 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.22 | 0.19 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.28 | 0.30 | 0.30 | 0.31 | 0.28 | 0.29 | 0.34 | 0.35 | 0.32 | 0.34 | 0.33 | 0.31 | 0.31 | 0.32 | 0.31 | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 0.04 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.19 | 0.21 | 0.20 | 0.21 | 0.22 | 0.23 | 0.25 | 0.26 | 0.35 | 0.36 | 0.31 | 0.31 | 0.31 | 0.30 | 0.29 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.13 | 0.15 | 0.16 | 0.17 | 0.15 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.32 | 0.33 | 0.36 | 0.37 | 0.29 | 0.28 | 0.28 | 0.31 | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Debt to assets = Total debt ÷ Total assets
= 6,279,200 ÷ 24,854,200 = 0.25
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Biogen Inc. debt to assets ratio improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Debt to Assets (including Operating Lease Liability)
Biogen Inc., debt to assets (including operating lease liability) calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Current portion of notes payable | —) | 999,800) | 999,500) | 999,100) | 998,800) | —) | —) | —) | —) | —) | 1,501,800) | 1,495,800) | 1,495,300) | —) | —) | —) | —) | —) | 3,300) | 3,200) | 573,200) | 559,900) | 561,500) | |||||||
| Notes payable, excluding current portion | 6,279,200) | 6,277,400) | 6,275,700) | 6,274,000) | 6,272,300) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 4,459,900) | 4,459,000) | 4,458,200) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,929,400) | 5,935,000) | 5,938,300) | 5,954,000) | 5,952,700) | |||||||
| Total debt | 6,279,200) | 7,277,200) | 7,275,200) | 7,273,100) | 7,271,100) | 7,269,200) | 7,267,200) | 7,426,200) | 7,425,000) | 7,423,800) | 5,961,700) | 5,954,800) | 5,953,500) | 5,948,500) | 5,943,200) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Long-term operating lease liabilities | 354,800) | 274,200) | 312,300) | 330,400) | 348,200) | 363,900) | 380,000) | 402,000) | 409,100) | 414,800) | 403,700) | 412,700) | 410,500) | 423,000) | 436,100) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Total debt (including operating lease liability) | 6,634,000) | 7,551,400) | 7,587,500) | 7,603,500) | 7,619,300) | 7,633,100) | 7,647,200) | 7,828,200) | 7,834,100) | 7,838,600) | 6,365,400) | 6,367,500) | 6,364,000) | 6,371,500) | 6,379,300) | 5,936,500) | 5,931,100) | 5,928,400) | 5,932,700) | 5,938,200) | 6,511,500) | 6,513,900) | 6,514,200) | |||||||
| Total assets | 24,854,200) | 25,081,400) | 23,614,400) | 23,877,300) | 23,806,700) | 24,470,400) | 23,854,700) | 24,618,900) | 24,934,100) | 25,511,800) | 26,119,200) | 27,234,300) | 27,484,000) | 26,287,600) | 26,445,500) | 25,288,900) | 25,492,200) | 23,952,900) | 26,090,100) | 23,652,600) | 23,073,200) | 21,759,000) | 21,195,900) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Debt to assets (including operating lease liability)1 | 0.27 | 0.30 | 0.32 | 0.32 | 0.32 | 0.31 | 0.32 | 0.32 | 0.31 | 0.31 | 0.24 | 0.23 | 0.23 | 0.24 | 0.24 | 0.23 | 0.23 | 0.25 | 0.23 | 0.25 | 0.28 | 0.30 | 0.31 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||||||
| Moderna Inc. | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 | 0.05 | 0.07 | 0.08 | 0.03 | 0.03 | 0.02 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 6,634,000 ÷ 24,854,200 = 0.27
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Biogen Inc. debt to assets ratio (including operating lease liability) improved from Q1 2022 to Q2 2022 and from Q2 2022 to Q3 2022. |
Financial Leverage
Biogen Inc., financial leverage calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||
| Total assets | 24,854,200) | 25,081,400) | 23,614,400) | 23,877,300) | 23,806,700) | 24,470,400) | 23,854,700) | 24,618,900) | 24,934,100) | 25,511,800) | 26,119,200) | 27,234,300) | 27,484,000) | 26,287,600) | 26,445,500) | 25,288,900) | 25,492,200) | 23,952,900) | 26,090,100) | 23,652,600) | 23,073,200) | 21,759,000) | 21,195,900) | |||||||
| Total Biogen Inc. shareholders’ equity | 12,775,500) | 11,872,500) | 11,242,300) | 10,896,200) | 10,429,900) | 10,751,900) | 10,682,200) | 10,700,300) | 10,758,500) | 11,308,700) | 12,546,900) | 13,343,200) | 13,995,900) | 12,952,900) | 13,829,900) | 13,039,600) | 13,766,600) | 12,260,900) | 14,053,700) | 12,612,800) | 12,860,500) | 11,585,200) | 11,479,000) | |||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||
| Financial leverage1 | 1.95 | 2.11 | 2.10 | 2.19 | 2.28 | 2.28 | 2.23 | 2.30 | 2.32 | 2.26 | 2.08 | 2.04 | 1.96 | 2.03 | 1.91 | 1.94 | 1.85 | 1.95 | 1.86 | 1.88 | 1.79 | 1.88 | 1.85 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 8.84 | 9.77 | 8.80 | 9.51 | 10.99 | 11.77 | 10.98 | 11.51 | 9.80 | 10.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 17.44 | 24.51 | 64.62 | 9.13 | 7.91 | 7.25 | 6.70 | 6.69 | 5.90 | 6.10 | 6.50 | 6.17 | 5.45 | 5.50 | 5.91 | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.01 | 3.08 | 3.26 | 3.04 | 2.98 | 3.01 | 2.99 | 3.13 | 2.50 | 2.61 | 2.59 | 2.52 | 3.25 | 3.44 | 2.29 | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 1.72 | 1.76 | 1.80 | 1.84 | 1.90 | 1.82 | 1.87 | 1.92 | 1.92 | 1.97 | 2.22 | 2.05 | 1.89 | 1.66 | 1.64 | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 4.71 | 5.51 | 5.03 | 5.44 | 6.21 | 7.42 | 6.79 | 8.27 | 9.10 | 10.25 | 13.35 | 15.07 | 11.20 | 13.91 | 15.32 | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.97 | 3.11 | 3.17 | 3.23 | 3.13 | 3.45 | 3.56 | 3.76 | 3.49 | 3.10 | 2.71 | 2.74 | 2.87 | 2.79 | 2.86 | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 2.35 | 2.33 | 2.39 | 2.46 | 2.55 | 2.54 | 2.62 | 2.76 | 2.65 | 2.51 | 2.53 | 2.65 | 2.67 | 2.55 | 2.54 | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 2.41 | 2.48 | 2.61 | 2.77 | 2.61 | 2.72 | 3.37 | 3.62 | 3.08 | 3.28 | 3.24 | 3.26 | 3.10 | 3.04 | 2.99 | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 1.45 | 1.45 | 1.62 | 1.74 | 2.07 | 2.41 | 3.31 | 2.86 | 1.69 | 1.18 | 1.26 | 1.35 | 1.27 | 1.26 | 1.25 | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 2.10 | 2.24 | 2.23 | 2.35 | 2.37 | 2.43 | 2.31 | 2.44 | 2.74 | 2.77 | 2.56 | 2.65 | 2.62 | 2.62 | 2.64 | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.29 | 1.32 | 1.32 | 1.36 | 1.37 | 1.42 | 1.48 | 1.56 | 1.59 | 1.59 | 1.30 | 1.34 | 1.33 | 1.35 | 1.36 | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 2.08 | 2.14 | 2.26 | 2.33 | 1.90 | 1.84 | 1.88 | 2.00 | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q3 2022 Calculation
Financial leverage = Total assets ÷ Total Biogen Inc. shareholders’ equity
= 24,854,200 ÷ 12,775,500 = 1.95
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Biogen Inc. financial leverage ratio increased from Q1 2022 to Q2 2022 but then decreased significantly from Q2 2022 to Q3 2022. |